Fifty 410 vs Henry Meds (2026): prices, structure, verdict
On tirzepatide, only Henry Meds↗ has a rankable figure: $349 a month all-in; Fifty 410↗ publishes no maintenance-dose tirzepatide figure we could capture (advertised start: $133), so a like-for-like number does not exist.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
On semaglutide, only Henry Meds has a rankable figure: $179 a month all-in; Fifty 410 does not offer semaglutide.
Fifty 410
- Tirzepatide all-in
- from $133 · no maintenance figure
- Semaglutide all-in
- not offered
- 12-mo tirzepatide (best path)
- —
- Membership
- none
- Shipping
- unknown
- Commitment
- unknown
- Cancellation
- not published
- Pharmacy
- not named
- States
- not published
- Insurance
- no
- Evidence
- source-verified · 2026-08-05
Henry Meds
- Tirzepatide all-in
- $349/mo · flat
- Semaglutide all-in
- $179/mo · flat
- 12-mo tirzepatide (best path)
- $4,188
- Membership
- none
- Shipping
- included
- Commitment
- none month-to-month
- Cancellation
- check terms before prepaying
- Pharmacy
- not named
- States
- most states
- Insurance
- no
- Evidence
- third-party reported · 2026-08-05
The two records, condensed
Fifty 410: the record, condensed
On tirzepatide, Fifty 410 advertises from $133 — and publishes no maintenance-dose figure we could capture. A starter-only price cannot be annualized, cannot be ranked, and should be treated as the bottom of an unstated range: before enrolling on its strength, get the 10 mg price in writing, and if the program will not state it, price the program at its ceiling rather than its floor.
Operationally at Fifty 410: shipping unknown; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Fifty 410 page · visit Fifty 410 ↗
Henry Meds: the record, condensed
Henry Meds’s tirzepatide program bills $349 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Henry Meds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.
Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $349 is the whole subscription, which makes Henry Meds unusually easy to compare and unusually easy to leave.
To place the number: #10 of 17 verified programs, with the floor $134/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $100 a month. A year at this figure: $4,188 monthly-billed.
Henry Meds’s semaglutide program bills $179 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.
The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.
Context for that figure: it ranks #9 of 20 in the verified semaglutide index — $46/month above the floor (Oak Longevity, $133) — and sits $170 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $2,148.
Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗
Everything besides the price
Coverage: Fifty 410 publishes “not published”; Henry Meds publishes “most states” — for anything short of an explicit 50-state claim, intake is the final word.
Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.
Exit terms: Fifty 410 — unknown; not published. Henry Meds — none month-to-month; check terms before prepaying.
Evidence: Fifty 410 source-verified (captured 2026-08-05); Henry Meds third-party reported (2026-08-05).
The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.
Switching between Fifty 410 and Henry Meds
Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Fifty 410: not published; Henry Meds: check terms before prepaying) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.
Which one, for whom
Cheapest tirzepatide month-to-month: Henry Meds ($349).
Cheapest 12-month path: Henry Meds at $4,188 (monthly billing).
Cheapest semaglutide: Henry Meds ($179).
Without a shared rankable price, the verdict rests entirely on the structural axes above — and on which of these two makes your remaining questions answerable in writing before money moves.
Verdicts are computed from the records above — recompute them from the dataset. Full profiles: Fifty 410 · Henry Meds.
Frequently asked
Which is cheaper, Fifty 410 or Henry Meds?
On tirzepatide, only Henry Meds has a rankable figure: $349 a month all-in ; Fifty 410 publishes no maintenance-dose tirzepatide figure we could capture (advertised start: $133), so a like-for-like number does not exist. On semaglutide, only Henry Meds has a rankable figure: $179 a month all-in ; Fifty 410 does not offer semaglutide.
Is there a membership fee at Fifty 410 or Henry Meds?
Fifty 410: none. Henry Meds: none.
Where do these numbers come from?
From each provider's own published pages, captured 2026-08-05 (Fifty 410) and 2026-08-05 (Henry Meds), normalized to the all-in maintenance basis and archived. Full records: the provider pages and the public dataset.
Is Fifty 410 or Henry Meds dose-flat?
Fifty 410: no flat structure verified — get the maintenance-dose price in writing. Henry Meds: yes — flat across doses. Flat pricing turns the advertised number into a ceiling; tiered pricing makes it a floor.
Can I check both Fifty 410 and Henry Meds against their sources?
Yes — that is the design. Each record carries a capture date (2026-08-05 / 2026-08-05), a source link, and an archive link in the database; the figures on this page regenerate from those records, so any discrepancy you find is reportable and fixable sitewide in one pass.
What states do Fifty 410 and Henry Meds serve?
Fifty 410: not published. Henry Meds: most states. Telehealth availability rides on clinician licensure and pharmacy permits, so for anything short of an explicit 50-state claim the enrollment flow is the final word; the state-by-state index adds the known exceptions.
Is shipping included at Fifty 410 and Henry Meds?
Fifty 410: unknown. Henry Meds: included. Cold-chain delivery is a real cost; programs that fold it into the all-in figure remove a checkout surprise, and any separate shipping line belongs in your comparison math before the prices above are treated as equivalent.
Which is more transparent, Fifty 410 or Henry Meds?
On the checkable axes: pharmacy named — Fifty 410 no, Henry Meds no; state list — Fifty 410 published, Henry Meds published; cancellation terms — Fifty 410 published, Henry Meds published; evidence — source-verified vs third-party reported. Disclosure predicts disclosure in this market, and the axis where one of these two goes quiet is usually where your intake questions should get loud.